Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + HAIC
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Hepatic Arterial Infusion
01
Overview
This entity refers to a combination treatment regimen being evaluated by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, for the treatment of unresectable colorectal liver metastases. The regimen consists of **fruquintinib**, a selective small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), and **hepatic arterial infusion chemotherapy (HAIC)**, which in this context utilizes oxaliplatin and 5-fluorouracil (5-FU). Fruquintinib is an approved anti-angiogenic therapy in China for metastatic colorectal cancer. The HAIC component is a locoregional delivery method that targets liver-dominant disease by providing a high local drug concentration with a high first-pass effect. This combination is specifically being studied in patients who have progressed after at least two lines of systemic therapy.
- Brand names
- Elunate
- Other names
- fruquintinib plus HAICfruquintinib + oxaliplatin + 5-fluorouracilHAIC-Cancer Institute and Hospital, Chinese Academy of Medical Sciences-colorectal cancer
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on fruquintinib + HAIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + HAIC.